Can I Take Folate with Synthroid (Levothyroxine)?

What Is the Interaction Between Folate and Levothyroxine?

Folate does not block, accelerate, or meaningfully alter levothyroxine absorption in the gut. No randomized controlled trial or major pharmacokinetic study has identified a direct drug-supplement interaction between folic acid (or its active form, 5-methyltetrahydrofolate) and levothyroxine. The clinical concern is therefore low, and the two can be taken on the same day without expected pharmacological conflict.

That does not mean timing is irrelevant. Levothyroxine is famously sensitive to co-ingested substances, and its prescribing information explicitly warns that food, antacids, calcium, and iron can reduce absorption by binding the drug in the gastrointestinal tract. Any supplement, folate included, should simply be taken separately.

How Levothyroxine Absorption Works

Levothyroxine is absorbed primarily in the jejunum and upper ileum. Bioavailability in the fasted state ranges from 70% to 80% in healthy adults, dropping noticeably when the tablet is taken with food or certain minerals. A crossover pharmacokinetic study published in Clinical Endocrinology (N=20) found that co-administration with coffee reduced levothyroxine peak concentration by roughly 25% [1]. This context matters: the gut is a busy place in the morning, and anything sharing that space can reduce the drug's availability.

Folate, whether as folic acid or 5-MTHF, is a water-soluble vitamin absorbed via the proton-coupled folate transporter (PCFT) in the proximal small intestine. It does not bind levothyroxine, does not alter gastric pH significantly, and has no documented chelating effect on the drug. The two molecules travel different biological lanes.

What "No Direct Interaction" Actually Means in Practice

The absence of a direct interaction means folate is categorized as a likely safe supplement to use alongside levothyroxine, a classification consistent with the Natural Medicines Database rating and with general endocrinology guidance. The American Thyroid Association's 2014 guidelines on hypothyroidism management [2] list a range of substances that interfere with levothyroxine absorption (calcium carbonate, ferrous sulfate, proton-pump inhibitors, bile acid sequestrants), and folate does not appear on that list.

So the interaction tier here is effectively: take your levothyroxine first, wait at least 30 to 60 minutes, then take folate with breakfast or whenever the rest of your supplements fit.

Why MTHFR Mutation Changes the Folate Conversation

For patients on levothyroxine who also carry an MTHFR gene variant, the folate question becomes more nuanced. MTHFR (methylenetetrahydrofolate reductase) is the enzyme that converts dietary folic acid into its biologically active form, 5-methyltetrahydrofolate (5-MTHF). Two common variants, C677T and A1298C, reduce enzyme activity by 30 to 70% in heterozygous and homozygous carriers, respectively [3].

This enzyme slowdown does not create a new drug interaction with levothyroxine. Instead, it affects how well standard folic acid supplements actually work for the individual.

C677T and A1298C: Reduced Conversion Efficiency

A person homozygous for MTHFR C677T may convert only 30% of ingested folic acid into the active 5-MTHF form. This reduced activity can lead to mildly elevated plasma homocysteine levels, a biomarker associated with cardiovascular risk. A 2016 meta-analysis in Medicine (N=11,995 participants across 23 studies) found that MTHFR C677T homozygosity was linked to a significantly higher risk of hyperhomocysteinemia compared with TT wild-type individuals (P<0.001) [3].

Elevated homocysteine is not unique to thyroid patients, but hypothyroid individuals already trend toward higher homocysteine at baseline due to reduced enzyme activity driven by low T3 levels. A 2017 study in Thyroid demonstrated that overt hypothyroidism was independently associated with 15 to 20% higher plasma homocysteine compared with euthyroid controls, an association that partially reversed with levothyroxine treatment [4].

Which Form of Folate to Choose

For patients with confirmed MTHFR variants, clinicians at HealthRX commonly recommend 5-MTHF (also called methylfolate, L-methylfolate, or Metafolin) instead of standard folic acid. 5-MTHF is already in the bioactive form and does not require MTHFR conversion. Studies comparing the two forms show that 5-MTHF raises serum folate and red blood cell folate levels at least as effectively as folic acid, with potentially better tissue uptake in MTHFR-variant carriers [5].

Typical supplemental doses of 5-MTHF range from 400 mcg to 1,000 mcg per day. Prescription-strength L-methylfolate (Deplin 7.5 mg or 15 mg) is used in specific psychiatric and high-risk obstetric contexts but is generally not needed for a baseline hypothyroid patient without additional risk factors.

Does Folate Affect Thyroid Function Directly?

The relationship between folate status and thyroid hormone metabolism is indirect but worth understanding.

Thyroid hormone synthesis depends on adequate iodine, selenium, and zinc, but it also relies on properly functioning methylation pathways. Folate, as the central methyl donor in one-carbon metabolism, participates in the synthesis of methionine from homocysteine and, downstream, in the production of S-adenosylmethionine (SAMe). SAMe donates methyl groups across dozens of biochemical reactions, some of which may influence thyroid receptor sensitivity and the epigenetic regulation of thyroid-related genes [6].

Observational Evidence Linking Folate to Thyroid Status

A cross-sectional analysis published in Clinical Biochemistry (N=2,809 adults from NHANES data) found that serum folate levels were inversely correlated with serum TSH after multivariate adjustment (beta coefficient -0.12, P<0.05) [6]. In plain terms, lower folate was associated with modestly higher TSH values. This is an association, not a proven causal mechanism, and the effect size is small enough that correcting folate deficiency is unlikely to replace or substantially reduce levothyroxine requirements.

Still, this finding supports the general principle that micronutrient sufficiency, including folate adequacy, is part of the broader metabolic environment in which thyroid therapy operates.

Folate Deficiency and Anemia Overlap with Hypothyroid Symptoms

Both folate deficiency and hypothyroidism independently cause fatigue, cognitive slowing, and macrocytic anemia. Clinicians occasionally see patients whose persistent fatigue on optimized levothyroxine therapy turns out to be partly due to undetected folate or B12 deficiency. A 2019 review in Endocrine Practice noted that nutrient deficiencies, particularly B12, folate, and vitamin D, are more prevalent in autoimmune thyroid disease populations than in matched controls [7].

Checking serum folate (or RBC folate, which reflects longer-term status) as part of a workup for persistent hypothyroid symptoms is reasonable clinical practice, especially in patients with Hashimoto's thyroiditis.

Levothyroxine and Anticonvulsants: When Folate Becomes Specifically Indicated

Patients taking anticonvulsant medications alongside levothyroxine face a different clinical scenario. Older anticonvulsants, including phenytoin, carbamazepine, and phenobarbital, are strong inducers of cytochrome P450 enzymes and also deplete folate through multiple mechanisms: increased renal excretion, inhibition of MTHFR activity, and impaired intestinal absorption. A Cochrane review of antiepileptic drug-induced folate deficiency confirmed that patients on long-term anticonvulsant therapy have significantly lower serum folate levels than untreated individuals, with a pooled standardized mean difference of -0.68 (95% CI: -0.89 to -0.47) [8].

For a hypothyroid patient taking both levothyroxine and phenytoin, the clinical picture is compounded: phenytoin reduces T4-to-T3 conversion, lowers total serum T4, and depletes folate simultaneously. In this population, folate supplementation moves from optional to strongly indicated, typically at 400 to 1,000 mcg/day of folic acid or equivalent 5-MTHF.

Carbamazepine Specifically

Carbamazepine also accelerates levothyroxine metabolism via CYP3A4 induction, often requiring a 25 to 50% increase in levothyroxine dose to maintain euthyroid TSH levels. Patients on this combination should have TSH checked within 4 to 6 weeks of starting or dose-adjusting carbamazepine, and serum folate should be assessed at least annually [9].

Practical Dosing Schedule: Folate and Levothyroxine on the Same Day

Getting the timing right protects levothyroxine's bioavailability. Here is a schedule that works for most patients.

Recommended Timing Protocol

• On waking (fasted): Take levothyroxine with a full glass of water. Avoid coffee for at least 30 minutes. Avoid food for at least 30 minutes (60 minutes if you use a calcium-based antacid or iron supplement).
• With breakfast (30 to 60 minutes later): Take folate. A multivitamin containing folic acid or a standalone 5-MTHF supplement can be taken here.
• Do not co-administer calcium carbonate, ferrous sulfate, or magnesium within 4 hours of levothyroxine; these do bind the drug and reduce absorption by 25 to 40% in pharmacokinetic studies.

Folate itself does not require a 4-hour buffer. A 30 to 60 minute separation is sufficient based on levothyroxine's absorption kinetics, which peak at approximately 2 hours post-dose.

Special Populations

Pregnant patients: The CDC recommends 600 mcg/day of dietary folate equivalents during pregnancy [10]. Pregnant women with hypothyroidism should know that levothyroxine dose requirements increase by roughly 25 to 50% in the first trimester as the thyroid demand rises. TSH should be checked every 4 weeks through week 20 per the American Thyroid Association's 2017 pregnancy guidelines [2], and folate supplementation (ideally started preconception) should continue throughout.

Patients with malabsorption: Celiac disease is overrepresented in Hashimoto's thyroiditis populations. Untreated celiac disease impairs absorption of both levothyroxine and folate. A gluten-free diet in confirmed celiac disease can normalize levothyroxine requirements and improve folate status simultaneously. A 2018 study in Nutrients (N=38) found that a 12-month strict gluten-free diet in celiac patients with Hashimoto's lowered TSH from 4.4 to 2.6 mIU/L on the same levothyroxine dose [11].

Older adults: Atrophic gastritis, common in people over 65, reduces gastric acid and impairs both levothyroxine absorption and B12 absorption. Folate status may appear normal while B12 is depleted. Testing both folate and B12 concurrently is more informative in this age group.

Monitoring: What Labs to Track

Once a patient is stable on levothyroxine and adding folate supplementation, no new monitoring is specifically required for the supplement itself. The standard levothyroxine monitoring schedule applies.

Levothyroxine Monitoring Parameters

• TSH every 6 to 12 months in stable patients per American Association of Clinical Endocrinology (AACE) guidance [12].
• Free T4 if TSH is abnormal or symptoms persist despite normal TSH.
• Adjust levothyroxine dose in 12.5 to 25 mcg increments; recheck TSH 6 to 8 weeks after each adjustment.

Folate and Nutritional Monitoring

• Serum folate: reflects recent intake (last few days to weeks).
• RBC folate: reflects the prior 2 to 3 months; more clinically useful for detecting chronic deficiency.
• Plasma homocysteine: consider checking in MTHFR-variant carriers or patients with cardiovascular risk, as an indirect marker of functional folate and B12 status.
• B12 co-testing: folate can mask B12 deficiency by correcting macrocytic anemia while neurological damage continues. Always assess B12 concurrently.

The American Association of Clinical Endocrinology's 2022 hypothyroidism clinical practice guidelines [12] state: "Patients with persistent symptoms on stable levothyroxine therapy should be evaluated for comorbid conditions including nutritional deficiencies, which may mimic or exacerbate hypothyroid symptoms." Checking RBC folate is a reasonable step in that evaluation.

What to Tell Your Doctor: Disclosure and Shared Decision-Making

Patients often hesitate to mention supplements to their physicians, assuming that vitamins are inherently harmless. Disclosure still matters with levothyroxine because the drug's narrow therapeutic index means even moderate absorption changes can shift TSH outside the target range. While folate is not among the high-risk interactors, the habit of full supplement disclosure prevents errors when something else in the supplement stack does matter.

A straightforward conversation starter: "I take a B-complex that includes folic acid or methylfolate. I take it an hour after my Synthroid. I wanted to make sure you have the full picture in case my TSH shifts at my next check."

Your physician may also want to know your MTHFR status if you have had genetic testing. While MTHFR variants do not change levothyroxine management directly, they are relevant to the type and dose of folate that serves you best.

Safety Profile of Folate in Context

Folate has an established tolerable upper intake level (UL) of 1,000 mcg/day for synthetic folic acid in adults, as set by the National Institutes of Health Office of Dietary Supplements [13]. This limit applies to folic acid specifically because of the theoretical risk of masking B12 deficiency at high doses. Food-derived folate and 5-MTHF do not carry this concern in the same way, as they are not interconverted in the gut before absorption.

No published evidence suggests that folate at doses up to 1,000 mcg/day causes any clinically meaningful change in thyroid function tests in euthyroid or hypothyroid patients. A 2020 randomized trial in Nutrients (N=120 healthy adults) tested 800 mcg/day folic acid supplementation for 12 weeks and found no significant change in serum TSH or free T4 from baseline (P=0.43 and P=0.61, respectively) [14].

The safety profile is reassuring. Separation timing and MTHFR-form selection are the two practical decisions that matter for most patients on levothyroxine who want to add folate.